Cipla Limited (CIPLA) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally.

Total Revenue Chart for Cipla Limited

Cipla Limited (CIPLA) revenue for FY2026 was INR 281.6B, a 3.3% change from FY2025. Cipla Limited's revenue grew from INR 18.4B in 2004 to INR 281.6B in 2026 (1428.7% over 22 years). Earnings per share grew from INR 17.27 in 2014 to INR 65.24 in 2025 (277.8%). Revenue compound annual growth rate: 5-year CAGR of 8.1%, 10-year CAGR of 7.6%, 20-year CAGR of 12.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (Indian Rupees)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
₹1.14T
Implied Share Price
₹1406.10
Enterprise Value
₹1.05T
Revenue (TTM)
₹280.68B
EBITDA
₹51.83B
Profit Margin
12.01%
Trailing P/E
34.21
Forward P/E
24.33
Price/Book (MRQ)
3.34
Price/Sales (TTM)
4.05
EV/EBITDA
18.40
EV/Revenue
3.77
Dividend Yield
0.00%
Book Value
₹426.25
Free Cash Flow (FY2026)
₹25.27B
Free Cash Flow Yield
2.22%

Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.